Mitsui Chemicals has signed an agreement to acquire JSR Corp., a Tokyo-based developer and manufacturer of semiconductor materials including photoresists, from investment funds managed by JIC Capital. The transaction values JSR at ¥1.84 trillion, or $11.6 billion, including debt, and would make JSR a consolidated subsidiary of Mitsui Chemicals.
Mitsui Chemicals will acquire all JSR common shares held by JIC PEFJ1 Limited Partnership and JIC PEF1 Limited Partnership, alongside DBJ, which will invest ¥200 billion ($1.3 billion). The consideration consists of ¥1.3921 trillion ($8.8 billion) in equity value and ¥447.9 billion ($2.8 billion) in interest-bearing debt and other items, subject to adjustment at closing. Mitsui also expects to acquire JSR’s Class A and Class B preferred shares from Mizuho Bank and DBJ for cash. Those shares are to convert to common shares after closing, while DBJ’s common shares will convert to non-voting preferred shares.
Strategic fit in ICT materials
The acquisition is intended to support Mitsui Chemicals’ VISION 2030 plan, which combines a specialty chemicals pillar—Life & Healthcare Solutions, Mobility Solutions and ICT Solutions—with a Basic & Green Materials pillar centered on petrochemicals. Mitsui said JSR’s advanced photoresists, customer base in semiconductors and optical fields, and global reach would make it a core part of ICT Solutions.
In front-end processes, Mitsui plans to combine its MITSUI PELLICLE products with JSR’s advanced photoresists. In back-end processes, it plans to pair its ICROS Tape with JSR’s thick-film resists. The company is targeting about ¥40 billion ($253 million) in annual incremental profit by fiscal 2035 from growth and cost synergies.
Portfolio changes and financing
Mitsui Chemicals first said in May 2025 that it would consider splitting off its Basic & Green Materials business. It now plans to add Mobility Solutions to the split-off scope, aiming to form a polymer science company with an integrated polymer chain spanning upstream petrochemicals and downstream functional polymers. It also plans to become more asset-light in underperforming businesses, improve its cash conversion cycle and sell shareholdings.
JSR is separately reviewing its life sciences business—contract research and contract development and manufacturing—which it treats as non-core. Including that review, Mitsui expects benefits representing business value of ¥350 billion ($2.2 billion) or more.
Funding will come from a ¥1.64 trillion ($10.4 billion) bridge loan from Mitsui’s principal financial institutions and DBJ’s ¥200 billion investment. Net debt/EBITDA is expected to temporarily exceed 4x after closing. To protect an A-category credit rating, Mitsui plans to refinance the bridge loan within one year using bank loans, bonds and equity. It aims to have the equivalent of ¥300 billion ($1.9 billion) recognized as equity by rating agencies, capping common share issuance, including treasury shares, at ¥150 billion ($948 million) and adding ¥300 billion of mezzanine financing, of which 50% is assumed to count as equity.
The company filed a shelf registration on Nov. 9 for up to ¥150 billion of common shares. It becomes effective Nov. 17, 2026, and runs through Nov. 16, 2028, with proceeds used for partial repayment of the bridge loan. SMBC Nikko Securities and Mizuho Securities are expected to be the primary underwriters.
Assets, approvals and outlook
Four JSR affiliates will become specified subsidiaries of Mitsui Chemicals: Inpria Corp. in Corvallis, Ore.; KBI Biopharma in Durham, N.C.; JSR North America Holdings in Sunnyvale, Calif.; and JSR Life Sciences in Sunnyvale. JSR reported revenue of ¥440.7 billion ($2.8 billion), consolidated operating profit of ¥40.5 billion ($256 million) and profit attributable to owners of ¥59.3 billion ($375 million) for the fiscal year ended March 2026.
The transaction is subject to competition-law and foreign-investment approvals in Japan and overseas. Mitsui Chemicals aims to close in the second half of the fiscal year ending March 2028 and expects the impact on results for the fiscal year ending March 2027 to be minor. The announced dollar figures use an exchange rate of ¥158.2 per $1.